The MHC-peptide complexes can be targeted by particular bsAbs, such as immune-cell-mobilizing monoclonal TCRs against cancer molecules (ImmTAC), which include an anti-CD3 scFv linked to a high-affinity TCR that recognizes target MHC-peptide complexes [116,117]. This evidence concerns the gene HLA-C and cancer.